Sign in

    Anthony Corbin

    Research Analyst at Goldman Sachs

    Anthony Corbin is an equity research analyst at Goldman Sachs specializing in healthcare sector coverage, with a particular focus on biotechnology and pharmaceutical companies. He covers firms such as Amgen, Gilead Sciences, and Regeneron, consistently delivering actionable investment research; available third-party data suggests he maintains a success rate above 60% with positive average returns over multi-year periods. Corbin began his finance career as an analyst at a boutique investment firm before joining Goldman Sachs in 2017, where he advanced quickly due to his sector expertise and rigorous analytical approach. He holds FINRA Series 7, 63, and 86/87 licenses and has been recognized for his insightful company analyses by both institutional clients and independent ranking platforms.

    Anthony Corbin's questions to Artisan Partners Asset Management (APAM) leadership

    Anthony Corbin's questions to Artisan Partners Asset Management (APAM) leadership • Q2 2025

    Question

    Anthony Corbin from Goldman Sachs inquired about Artisan Partners' M&A strategy, particularly the asset classes of interest in alternatives, and the potential timing for reopening capacity-constrained funds.

    Answer

    CEO Jason Gottlieb detailed the firm's talent-driven M&A approach, highlighting interest in value-add/opportunistic real estate, private equity secondaries, and asset-based lending, noting a high volume of deal flow. Executive Chair Eric Colson addressed capacity, explaining they are managing it carefully in growth strategies and working with existing intermediated wealth clients for constrained strategies like international value and high income.

    Ask Fintool Equity Research AI

    Anthony Corbin's questions to Artisan Partners Asset Management (APAM) leadership • Q1 2025

    Question

    Anthony Corbin of Goldman Sachs & Co. inquired about growth opportunities in fixed income and alternatives, particularly within the retail and insurance channels, and also asked for guidance on normalized expenses and margin maintenance levers.

    Answer

    President Jason Gottlieb detailed two growth paths for fixed income and alternatives: expanding degrees of freedom for existing teams like High Income and EMsights, and pursuing new growth via lift-outs or M&A. He highlighted the Global Unconstrained strategy as a key offering for the high-net-worth space. CFO C.J. Daley confirmed that full-year expense guidance remains intact, explaining that lower Q1 G&A from FX gains and reduced travel would be offset in later quarters, and that variable expenses move with revenue.

    Ask Fintool Equity Research AI